Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Dr. Tang has been working in Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS), since she got her PhD degree in 2005. She focuses on the therapeutic drug discovery for the treatment of autoimmune diseases and exploring their mechanisms of pharmacological action. After successfully formed a highly efficient screening and evaluation system and tested thousands of compounds and components from Chinese traditional and herbal medicines, several drug candidates have been found and are currently in the advanced stages of clinical development. She was elected as a “Young leading talent of scientific and technological innovation” from the Ministry of Science and Technology of China.

EDUCATION

2002-2005 Dsc. in Immunopharmacology in Shanghai Institue of Materia Medica

1999-2002 Msc. in Pharmacology at Xinjiang Medical University

1992-1997 MD. at Xinjiang Medical University

WORK EXPERIENCE

2007- date Shanghai Institue of Materia Medica

2005-2007 Assistant Professor in Immunopharmacology in Shanghai Institue of Materia Medica

1997-2002 Teaching Assistant in Department of Pharmacology at Xinjiang Medical University

Research Directions

Dedicating on the drug discovery and evaluation for treatment of autoimmune diseases (psoriasis, IBD, nephritis, et al), viral infectious diseases (HBV, HCV, DV, Flu, et al) and exploring their mechanisms of pharmacological action.

Grants & Research Projects

Achievements

Formed a highly efficient screening and evaluation system for immunosuppressive drug candidate discovery which includes in vitro and in vivo study. Several series of promising candidates for the treatment of autoimmune diseases have been confirmed.

morefold

Social Titles

morefold

Awards & Honors

morefold

Pubilcations

Full Publication List

Selected Publications

1.Li H, Feng C, Fan C, Yang Y, Yang X, Lu H, Lu Q, Zhu F, Xiang C, Zhang Z, He P, Zuo J, Tang W. Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis. Cell Death Dis. 2020 Apr 24;11(4):271.

2.Wu Y, Wu B, Zhang Z, Lu H, Fan C, Qi Q, Gao Y, Li H, Feng C, Zuo J, Tang W. Heme protects intestinal mucosal barrier in DSS-induced colitis through regulating macrophage polarization in both HO-1-dependent and HO-1-independent way. FASEB J. 2020 Apr 17.

3.Li H, Li J, Zhang X, Feng C, Fan C, Yang X, Zhang R, Zhu F, Zhou Y, Xu Y, Liu H, Tang W*. DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling. Biochem Pharmacol. 2020 Apr 3:113958.

4.Li H, Fan C, Lu H, Feng C, He P, Yang X, Xiang C, Zuo J*, Tang W*.. Protective role of berberine on ulcerative colitis through modulating enteric glial cells-intestinal epithelial cells-immune cells interactions. Acta Pharm Sin B. 2020 Mar;10(3):447-461.

5.Xie Z, Wu B, Liu Y, Ren W, Tong L, Xiang C, Wei A, Gao Y, Zeng L, Xie H*, Tang W*, Hu Y*. Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders. J Med Chem. 2020 Feb 13;63(3):1397-1414.

6.Lu H, Li H, Fan C, Qi Q, Yan Y, Wu Y, Feng C, Wu B, Gao Y, Zuo JP*, WeiTang*. RIPK1 inhibitor ameliorates colitis by directly maintaining intestinal barrier homeostasis and regulating following IECs-Immuno crosstalk. Biochem Pharmacol. 2020 Feb;172:113751

7.Zhang Z, Wu Y, Wu B, Qi Q, Li H, Lu H, Fan C, Feng C, Zuo J*, Niu L*, Tang W*. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. Arthritis Res Ther. 2019 Dec 16;21(1):290.

8.Wu B, Wu YW*, Tang W*. Heme Catabolic Pathway in Inflammation and Immune Disorders. Front. Pharmacol. 2019 Jul 24;10:825.

9.Yang M, Li H, Zhang Q, Wu QH, Li G, Chen KX, Guo YW*, Tang W*, Li XW*. Highly diverse cembranoids from the South China Sea soft coral Sinularia scabra as a new class of potential immunosuppressive agents. Bioorg Med Chem. 2019 Aug 1;27(15):3469-3476.

10.Zhang X, Dong G, Li H, Chen W, Li J, Feng C, Gu Z, Zhu F, Zhang R, Li M, Tang W*, Liu H*, Xu Y*. Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Anti-Psoriasis Agent. J Med Chem. 2019 Jun 13;62(11):5579-5593.

11.Li H, Fan C, Feng C, Wu Y, Lu H, He P, Yang X, Zhu F, Qi Q, Gao Y, *Zuo J, *Tang W. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity. Br J Pharmacol. 2019 Jul;176(13):2209-2226.

12.Li G, Li H, Zhang Q, Yang M, Gu YC, Liang LF*, Tang W*, Guo YW*. Rare Cembranoids from Chinese Soft Coral Sarcophyton ehrenbergi: Structural and Stereochemical Studies. J Org Chem. 2019 May 3;84(9):5091-5098.

13.He S, Liu X, Lin Z, Liu Y, Gu L, Zhou H*, Tang W*, Zuo J*. Reversible SAHH inhibitor protects against glomerulonephritis in lupus-prone mice by downregulating renal α-actinin-4 expression and stabilizing integrin-cytoskeleton linkage. Arthritis Res Ther. 2019 Jan 29;21(1):40.

14.Yang M, Liang LF, Li H, Tang W*, Guo YW*. A new 5α,8α-epidioxysterol with immunosuppressive activity from the South China Sea soft coral Sinularia sp. Nat Prod Res. 2019 Jan 29:1-6.

15.Liu J, Li H, Chen K, Zuo J, Guo YW, Tang W*, Li XW*. Design and Synthesis of Marine Phidianidine Derivatives as Potential Immunosuppressive Agents. J Med Chem. 2018 Nov 30.

16.Wang XF, Li H, Jiang K, Wang QQ, Zheng YH, Tang W*, Tan CH*. Anti-inflammatory constituents from Perilla frutescens on lipopolysaccharide-stimulated RAW264.7 cells. Fitoterapia. 2018 Oct;130:61-65.

17.Li H, Zuo J*, Tang W*. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol. 2018 Oct 17;9:1048.

18.Yan YX, Shao MJ, Qi Q, Xu YS, Yang XQ, Zhu FH, He SJ, He PL, Feng CL, Wu YW, Li H, Tang W*, Zuo JP*. Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages. Acta Pharmacol Sin. 2018 Oct;39(10):1633-1644.

19.Lin ZM, Ma M, Li H, Qi Q, Liu YT, Yan YX, Shen YF, Yang XQ, Zhu FH, He SJ, Tang W*, Zuo JP*. Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-γ-induced inflammatory response in keratinocytes and T cell-derived IL-17. Pharmacol Res. 2018 Mar;129:443-452.

20.Qi Q, Li H, Lin ZM, Yang XQ, Zhu FH, Liu YT, Shao MJ, Zhang LY, Xu YS, Yan YX, Sun LL, He SJ, Tang W*, Zuo JP*. (5R)-5-hydroxytriptolide ameliorates anti-glomerular basement membrane glomerulonephritis in NZW mice by regulating Fcγ receptor signaling. Acta Pharmacol Sin. 2018 Jan;39(1):107-116.

morefold